[8-K] NRX Pharmaceuticals, Inc. Reports Material Event

Rhea-AI Filing Summary

NRx Pharmaceuticals, Inc. reported that its audit committee has appointed Weinberg & Company P.A. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg previously audited the financial statements of Dura Medical LLC, which was acquired by Hope Therapeutics, Inc., a subsidiary of NRx.

As part of this change, the audit committee dismissed Salberg & Company P.A. as the company’s independent auditor on or around November 24, 2025. Salberg’s audit reports on the December 31, 2024 and December 31, 2023 consolidated financial statements contained an explanatory paragraph about NRx’s ability to continue as a going concern, but no adverse opinions, disclaimers, or qualifications.

The company states there were no disagreements or reportable events with Salberg under SEC definitions during the past two fiscal years and through September 30, 2025. Salberg provided a letter to the SEC confirming its agreement with NRx’s description of the relationship and the change in auditors.

Insights

Audit & governance specialist

NRx changes auditors with no reported disputes; impact appears neutral.

NRx Pharmaceuticals is transitioning its independent auditor from Salberg & Company P.A. to Weinberg & Company P.A. for the fiscal year ending December 31, 2025. Weinberg already audits Dura Medical LLC, which is linked to NRx through its subsidiary Hope Therapeutics, so the firm is familiar with part of the business.

The company notes that Salberg’s reports on the 2023 and 2024 financial statements included a going concern explanatory paragraph, but were otherwise unqualified. It also explicitly states there were no disagreements or reportable events with Salberg under Regulation S‑K definitions over the last two fiscal years and the interim period through September 30, 2025.

From an investor perspective, this looks like an orderly auditor change rather than a dispute-driven departure. The accompanying Salberg letter, filed as Exhibit 16.1, confirms Salberg agrees with NRx’s description of the relationship and the circumstances of its dismissal.

false 0001719406 0001719406 2025-11-20 2025-11-20 0001719406 nrxp:CommonStockCustomMember 2025-11-20 2025-11-20 0001719406 nrxp:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2025-11-20 2025-11-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2025

NRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

	Delaware		001-38302		82-2844431
	(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

	1201 Orange Street, Suite 600 Wilmington, Delaware		19801
	(Address of principal executive offices)		(Zip Code)

(484)254-6134

(Registrant’s telephone number, including area code)      

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.424)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, par value $0.001 per share	NRXP	The Nasdaq Stock Market LLC
Warrants to purchase one share of Common Stock	NRXPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01 Changes in Registrant’s Certifying Accountant.

Engagement of New Independent Registered Public Accounting Firm and Dismissal of Independent Registered Public Accounting Firm

On November 20, 2025, the audit committee of the board of directors (the “Audit Committee”) of NRx Pharmaceuticals, Inc. (the “Corporation”) approved the engagement of Weinberg & Company P.A. (“Weinberg”) as the Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg had been previously engaged to audit the financial statements of Dura Medical LLC, which had been acquired by Hope Therapeutics, Inc. (“HOPE”), a subsidiary of the Corporation. During the Corporation’s two most recent fiscal years and the subsequent interim period through September 30, 2025, neither the Corporation, nor anyone on its behalf, consulted Weinberg regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Corporation’s financial statements, and neither a written report nor oral advice was provided to the Corporation that Weinberg concluded was an important factor considered by the Corporation in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K.

For the reason stated above, on or around November 24, 2025 the Audit Committee of the Corporation dismissed Salberg & Company P.A. (“Salberg”) as the Corporation’s independent registered public accounting firm.

Salberg’s audit reports on the Corporation’s consolidated financial statements for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the audit opinion contained an explanatory paragraph regarding the Company’s ability to continue as a going concern.

During the Corporation’s two most recent fiscal years, which ended December 31, 2024 and December 31, 2023, and the subsequent interim period through September 30, 2025, (i) there were no “disagreements” (within the meaning set forth in Item 304(a)(1)(iv) of Regulation S-K) between the Corporation and Salberg on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Salberg’s satisfaction, would have caused Salberg to make reference to the subject matter of the disagreements in connection with their reports; and (ii) there were no “reportable events” (within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K).

In accordance with Item 304(a)(3) of Regulation S-K, the Corporation provided Salberg with a copy of this Current Report on Form 8-K and requested that Salberg furnish the Corporation with a letter addressed to the United States Securities and Exchange Commission stating whether Salberg agrees with the above statements of the Corporation herein and, if not, stating the respects in which it does not agree. Salberg furnished the requested letter, stating its agreement with such statements, and a copy is filed as Exhibit 16.1 to this Current Report on Form 8-K.         

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
16.1*		Letter from Salberg & Company P.A. to the SEC dated November 25, 2025.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NRx Pharmaceuticals, Inc.
Date: November 26, 2025	By:	/s/ Jonathan Javitt
	Name:	Jonathan Javitt
	Its:	Interim Chief Executive Officer

FAQ

What accounting firm did NRx Pharmaceuticals (NRXP) appoint as its new auditor?

NRx Pharmaceuticals appointed Weinberg & Company P.A. as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Which auditor did NRx Pharmaceuticals (NRXP) dismiss and when?

The audit committee dismissed Salberg & Company P.A. as NRx’s independent registered public accounting firm on or around November 24, 2025.

Did NRx Pharmaceuticals (NRXP) report any disagreements with Salberg & Company?

No. NRx states that during the two most recent fiscal years and through September 30, 2025, there were no disagreements or reportable events with Salberg as defined in Items 304(a)(1)(iv) and 304(a)(1)(v) of Regulation S‑K.

What did Salbergs prior audit reports say about NRx Pharmaceuticals financial condition?

Salbergs audit reports on NRxs consolidated financial statements for the years ended December 31, 2024 and December 31, 2023 were unqualified but included an explanatory paragraph about the companys ability to continue as a going concern.

Why was Weinberg already familiar with part of NRx Pharmaceuticals business?

Weinberg & Company P.A. had previously been engaged to audit the financial statements of Dura Medical LLC, which was acquired by Hope Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals.

What is Exhibit 16.1 in this NRXP 8-K?

Exhibit 16.1 is a letter from Salberg & Company P.A. to the SEC, dated November 25, 2025, in which Salberg states it agrees with NRx Pharmaceuticals description of the auditor change.